July 15, 2008
On July 15, it was announced that ViroPharma Incorporated and Willkie client Lev Pharmaceuticals, Inc. signed a definitive merger agreement under which ViroPharma will acquire Lev for $442.9 million. Under the terms of the agreement, ViroPharma will acquire the outstanding common stock of Lev for $2.25 per share in cash and $0.50 per share in stock. Contingent consideration of up to $1.00 per share may be paid on achievement of certain regulatory and commercial milestones, bringing the value of the deal up to $617.5 million. Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. ViroPharma is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. The transaction was handled by partners Jeffrey Hochman, Thomas Meloro, Christopher Peters and David Rubinsky; special counsel Kim Walker; and associates Nicole Napolitano, Jeffrey Fang, Katie Calebrese and Bret Cohen.
